English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Johnson & Johnson
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Dec 20, 2019
JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Press release submission
| Jun 14, 2019
JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis
Trending
+
Technology/Innovation
Patient Daily
| May 8, 2025
Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+
Technology/Innovation
Patient Daily
| May 7, 2025
OTO Forum 2025 highlights innovation in ENT
+
Pharmaceuticals
Patient Daily
| May 8, 2025
Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+
Pharmaceuticals
Patient Daily
| May 8, 2025
National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments
